A 55-year-old male underwent a bilateral lung transplant in April 2014 for chronic obstructive pulmonary disease. Following transplantation, he received tacrolimus, mycophenolate, and prednisone along with trimethoprim-sulfamethoxazole and acyclovir for antimicrobial prophylaxis and azithromycin for immunomodulation. He had an uneventful posttransplant course until October 2017, when, during routine pulmonary function testing, his forced expiratory volume in 1 second (FEV1) was decreased to 75% when compared to his best posttransplant FEV1 along with reduction in forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) ratio to 60%. He was, however, asymptomatic. His chest radiograph was unremarkable, and the bronchoscopy did not show anatomic complications. Bronchoalveolar lavage (BAL) bacterial, fungal, and mycobacterial cultures were negative, and a transbronchial biopsy showed no evidence of acute cellular rejection. Mycophenolate was switched to azathioprine for immunomodulation, but the allograft dysfunction worsened.
His worsening lung function was attributed to bronchiolitis obliterans syndrome (BOS). In early January 2018, he received 6 doses of rATG (50 mg on Day 1 and Day 2; and 100 mg on Day 3, Day 4, Day 5, and Day 6) following premedication with methylprednisolone (1mg/kg on Days 1–4 and 0.5 mg/kg on Days 5 and 6) for management of BOS.

Six days after the last dose of rATG, he noted a diffuse body rash, myalgia, arthralgia, and fever of 39.1°C. Hepatomegaly and splenomegaly were absent on examination. His complete blood count showed leukocytosis of 12 700/mm³, hemoglobin of 12.5 g/dL and platelets count of 178 000/mm³. Basic metabolic and hepatic test results were normal. A chest radiograph was negative for pulmonary infiltrates. Vancomycin, cefepime, and oseltamivir were initiated empirically. However, his clinical symptoms were more consistent with rATG-induced serum sickness for which he received a single dose of methylprednisolone 40 mg. The clinical findings improved within 24 hours with resolution of fever and improvement of the rash, myalgia, and arthralgia. Blood cultures and a nasopharyngeal swab for influenza were negative. The antimicrobial treatment was discontinued and the patient was discharged on the fourth hospital day, receiving prednisone 7.5 mg daily and tacrolimus 2 mg twice daily.

At follow-up 1 week later, the patient was asymptomatic. However, the serum submitted during hospitalization was positive for the Blastomyces antigen at 0.9 ng/mL (normal range: none detected), but negative for the Histoplasma antigen (Table 1). A computed tomographic scan of the chest was unremarkable. Serum 1,3 β-D-glucan and Aspergillus galactomannan were negative. The clinical findings and response to corticosteroids were more consistent with serum sickness than fungal infection and the positive Blastomyces antigen was suspected to be falsely positive. Antifungal therapy was withheld and an additional evaluation for fungal infection was pursued. Repeat Blastomyces antigen testing in the serum was undetectable, but the Histoplasma antigen was weakly positive at 0.4 ng/mL (normal range: none detected) (Table 1). Both were negative in the urine.

The Histoplasma antigen was negative in the serum at follow-up at 6 weeks, but there was insufficient serum to repeat the Blastomyces antigen test. Histoplasma antibody testing by immunodiffusion and complement fixation were negative, but Blastomyces antibody testing was not performed.

MiraVista Diagnostics was consulted about the possibility of falsely positive antigen results. Additional studies were conducted to determine if the results were caused by the immunological response to rATG.

**METHODS**

Histoplasma and Blastomyces antigen detection was performed as previously described [8, 9]. Procedures to reduce the effect of HARA included adsorption of the biotinylated anti-Histoplasma antibody with normal rabbit serum (NRS) [4] and pretreatment of the serum with EDTA at 104°C [10].

**RESULTS**

Elimination of EDTA pretreatment caused an increase of the Histoplasma antigen from 0 ng/mL to 3.3 ng/mL in the week 0 serum (Table 1). Exclusion of NRS from the biotinylated detector antibody caused a further increase from 3.3 ng/ml in the presence of NRS to ≥19 ng/ml in the absence of NRS. Specimens from week 2 and week 6 were insufficient to evaluate the effect of EDTA pretreatment and NRS.

The elimination of EDTA pretreatment increased the Blastomyces antigen from 0.9 to 2.6 ng/mL in the week 0 specimen, and antigenemia persisted for 6 weeks. There was not adequate specimen to evaluate elimination of NRS in the Blastomyces antigen assay.

**DISCUSSION**

Blastomycosis and histoplasmosis in transplant recipients are usually treated with a lipid formulation of amphotericin B for a few weeks followed by triazoles for at least a year. The treatment can be complicated by amphotericin-B–associated adverse effects, including nephrotoxicity and electrolyte abnormalities. Other less serious adverse effects include triazole-related transaminitis, rashes, a prolonged QT interval, and drug interactions. The consequences of an incorrect diagnosis of a fungal infection and treatment with potentially toxic antifungal agents may be serious.

Several factors suggested that the antigen results may have been falsely positive in our patient. The donor did not have evidence of blastomycosis or histoplasmosis. Clinical findings of disseminated histoplasmosis such as colitis, hepatomegaly, splenomegaly, focal skin or mucosal lesions, and central nervous system findings were absent [3]. Our patient’s findings were rash and fever. Laboratory findings of disseminated histoplasmosis such as pancytopenia and hepatic laboratory abnormalities were absent [11].
Histoplasma antigenuria, found in 95% of transplant patients with histoplasmosis, was absent [3]. Antibodies to Histoplasma were also absent, although the antibody response is impaired in transplant patients [3].

Most patients with disseminated histoplasmosis require at least a few days of therapy to show clinical improvement [12]. Our patient improved within 24 hours of receiving methylprednisolone. Most importantly, our patient has not developed histoplasmosis or blastomycosis after a year of observation. Untreated disseminated histoplasmosis is rapidly fatal in immunocompromised patients [13].

Additional testing was helpful in establishing that the results were likely falsely positive. Demonstration that elimination of pretreatment of the serum with EDTA at 104°C and exclusion of NRS from the biotinylated detector antibody markedly increased the antigen concentration provides strong evidence that the positive result was caused by HARA.

Cross-reactions in other mycoses must also be considered in arriving at the correct diagnosis. Complete cross-reactivity occurs in histoplasmosis and blastomycosis, high-level cross-reactivity in paracoccidioidomycosis and Talaromyces marneffei infection [14], and low-level cross-reactivity in coccidioidomycosis [15]. Although histoplasmosis causes false-positive results for Aspergillus galactomannan in the serum, the converse has not been reported, except in BAL [16, 17].

CONCLUSION

Despite modification to the MiraVista antigen assay, false-positive results still occur in patients who have received rATG. Physicians are reminded to consider the possibility of false-positive results if clinical, radiographic, and laboratory findings do not support the diagnosis. Consultation with the laboratory performing the test is recommended for additional testing for HARA interference.

Acknowledgment

Author contributions. A.K. and K.G. are responsible for the manuscript writing and review of the literature; L.J.W. for manuscript writing, critical review, and interpretation of test results; M.M.D. for interpretation of the test results; and M.E. and J.K. for revision and critical review of the manuscript.

Financial support. None reported.

Potential conflicts of interest. L.J.W. and M.M.D. are employees of MiraVista Diagnostics. A.K., M.E., J.K.-T. and K.G. have no conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. Gauthier GM, Safdar N, Klein BS, Andes DR. Blastomycosis in solid organ transplant recipients. Transpl Infect Dis 2007; 9:310–7.
2. Vikram HR, Dosanjh A, Blair JE. Coccidioidomycosis and lung transplantation. Transplantation 2011; 92:717–21.
3. Assi M, Martin S, Wheat LJ, et al. Histoplasmosis after solid organ transplant. Clin Infect Dis 2013; 57:1542–9.
4. Wheat LJ, Connolly P, Durkin M, et al. False-positive Histoplasma antigenemia caused by antithymocyte globulin antibodies. Transpl Infect Dis 2004; 6:23–7.
5. Wheat LJ, Connolly P, Durkin M, et al. Elimination of false-positive Histoplasma antigenemia caused by human anti-rabbit antibodies in the second-generation Histoplasma antigen assay. Transpl Infect Dis 2006; 8:219–21.
6. Wheat LJ, Witt J III, Durkin M, Connolly P. Reduction in false antigenemia in the second generation Histoplasma antigen assay. Med Mycol 2007; 45:169–71.
7. Kricka LJ. Human anti-animal antibody interferences in immunological assays. Clin Chem 1999; 45:942–56.
8. Durkin M, Witt J, LeMonte A, et al. Antigen assay with the potential to aid in diagnosis of Blastomycosis. J Clin Microbiol 2004; 42:4873–5.
9. Connolly PA, Durkin MM, LeMonte AM, et al. Detection of Histoplasma antigen by a quantitative enzyme immunoassay. Clin Vaccine Immunol 2007; 14:1587–91.
10. Swartzentruber S, Rhodes J, Kurkjian K, et al. Diagnosis of acute pulmonary histoplasmosis by antigen detection. Clin Infect Dis 2009; 49:1878–82.
11. Sathapatayavongs B, Batteiger BE, Wheat J, et al. Clinical and laboratory features of disseminated histoplasmosis during two large urban outbreaks. Medicine 1983; 62:263–70.
12. Johnson PC, Wheat LJ, Cloud GA, et al.; U.S. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med 2002; 137:105–9.
13. Davies SE, Sarosi GA, Peterson PK, et al. Disseminated histoplasmosis in renal transplant recipients. Am J Surg 1979; 137:686–91.
14. Wheat J, Wheat H, Connolly P, et al. Cross-reactivity in Histoplasma capsulatum variety capsulatum antigen assays of urine samples from patients with endemic mycoses. Clin Infect Dis 1997; 24:1169–73.
15. Durkin M, Connolly P, Kuberski T, et al. Diagnosis of coccidioidomycosis with use of the Coccidioides antigen enzyme immunoassay. Clin Infect Dis 2008; 47:e69–73.
16. Hage CA, Davis TE, Fuller D, et al. Diagnosis of histoplasmosis by antigen detection in BAL fluid. Chest 2010; 137:623–8.
17. Vergidis P, Widker RC, Kaul DR, et al. False-positive Aspergillus galactomannan assay in solid organ transplant recipients with histoplasmosis. Transpl Infect Dis 2012; 14:213–7.